

Director's Share Dealing

London: Thursday, August 10, 2017: Hutchison China MediTech Limited ("Chi-Med") (AIM/Nasdaq: HCM) has received notifications that Ms Edith Shih, Non-executive Director and Company Secretary, purchased a total of 1,807 American Depositary Shares of the Company ("ADSs", each representing one half of one ordinary share of US\$1.00 each in the capital of Chi-Med) at an average price of US\$26.18 per ADS on August 7 and 9, 2017.

Following the above purchases, Ms Shih is interested in 85,663 ADSs and 70,000 Ordinary Shares, representing approximately 0.19% of the current issued share capital of Chi-Med.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

1	Details of the person discharging managerial responsibilities/person closely associated	
a)	Name	Ms Edith Shih
2	Reason for the notification	
a)	Position/status	Non-executive Director and Company Secretary
b)	Initial notification/Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor	
a)	Name	Hutchison China MediTech Limited
b)	LEI	2138006X34YDQ6OBYE79
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted	
a)	Description of the financial instrument, type of instrument Identification code	ADS each representing one half of one Ordinary Share of US\$1.00 ADS ISIN: US44842L1035
b)	Nature of the transaction	Acquisition of 1,807 ADSs on August 7 and 9, 2017 at an average price of US\$26.18 per ADS.
c)	Price(s) and volume(s)	Price(s)
		Volume(s)
		US\$26.10
		870
		US\$26.09
		200
		US\$25.98
		130

		US\$26.30	107
		US\$26.40	100
		US\$26.39	200
		US\$26.38	200
d)	Aggregated information - Aggregated volume - Price	Aggregated volume: 1,807 ADSs Price information: US\$26.18	
e)	Date of the transaction	2017-08-07 – acquisition of 1,200 ADSs 2017-08-09 – acquisition of 607 ADSs	
f)	Place of the transaction	Nasdaq Stock Market	

About Chi-Med

Chi-Med is an innovative biopharmaceutical company which researches, develops, manufactures and sells pharmaceuticals and healthcare products. Its Innovation Platform, Hutchison MediPharma Limited, focuses on discovering and developing innovative therapeutics in oncology and autoimmune diseases for the global market. Its Commercial Platform manufactures, markets, and distributes prescription drugs and consumer health products in China.

Chi-Med is majority owned by the multinational conglomerate CK Hutchison Holdings Limited (“CK Hutchison”) (SEHK: 0001). For more information, please visit: www.chi-med.com.

CONTACTS

Investor Enquiries

Mark Lee, +852 2121 8200
SVP Corporate Finance & Development

U.K. & International Media Enquiries

Anthony Carlisle, Citigate Dewe Rogerson +44 7973 611 888 (Mobile) anthony.carlisle@cdrconsultancy.co.uk

U.S. Based Media Enquiries

Brad Miles, BMC Communications +1 (917) 570 7340 (Mobile) bmiles@bmccommunications.com
Susan Duffy, BMC Communications +1 (917) 499 8887 (Mobile) sduffy@bmccommunications.com

Investor Relations

Matt Beck, The Trout Group +1 (917) 415 1750 (Mobile) mbeck@troutgroup.com
David Dible, Citigate Dewe Rogerson +44 7967 566 919 (Mobile) david.dible@citigatedr.co.uk

Panmure Gordon (UK) Limited

Richard Gray / Andrew Potts +44 (20) 7886 2500